On Wednesday, the British pharmaceutical giant AstraZeneca published new data showing the effectiveness of a phase 3 trial of the anti-Covid-19 drug “Evoshield”.
The results, published in The Lancet Respiratory Medicine, show that Evoshield “provides statistically significant protection against development or death from severe forms of COVID-19, or death from it, compared to using a placebo.”
The trial shows “the benefit of outpatient treatment with Evoshield for mild to moderate cases of Covid-19 infection,” according to the British group.
During the experiment, “90% of the participants were at risk of developing a severe form of COVID-19 due to comorbidities or age,” according to AstraZeneca.
The study was conducted at 95 sites in the United States, Latin America, Europe and Japan on 903 participants.
“Despite the success of vaccines, many people, especially the elderly or those with comorbidities or immunodeficiencies, are still at risk of contracting severe forms of Covid,” said Hugh Montgomery, professor of intensive care at University College London, who led the trial. -19″.
He continued, as quoted by the statement, “There is a need for other options to prevent the development of the disease and reduce pressure on health systems, especially in light of the emergence of new mutations.”
“We continue to discuss trial results with regulators,” said Mini Pangalos, executive vice president for research in biopharmaceuticals at AstraZeneca.
Evoshield has a license for marketing in the European Union and a conditional license in the UK for preventive treatments.
#AstraZeneca #publishes #results #experiment #antiCorona #drug